Market Overview:
The global bio contract development and manufacturing organizations (CDMOs) market is expected to grow at a CAGR of 9.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for outsourcing of bio-pharmaceutical services by pharmaceutical and biotechnology companies. In addition, the growing number of generic drug approvals is also contributing to the growth of this market. The API development segment is expected to account for the largest share of the global bio contract development and manufacturing organizations (CDMOs) market in 2018. This segment is expected to grow at a CAGR of 10% during the forecast period from 2018 to 2030.
 Industry Outlook.svg)
Product Definition:
A Bio Contract Development and Manufacturing Organization (CDMO) is an organization that provides contract development and/or manufacturing services to the life science industry. CDMOs offer a variety of services, including small-scale discovery chemistry, preclinical and clinical development, large-scale manufacturing, formulation development, and regulatory support. The use of CDMOs is becoming increasingly common in the life sciences industry as companies look to outsource noncore activities in order to focus on their core strengths. The importance of CDMOs lies in their ability to provide comprehensive services that can help companies bring new therapies to market more quickly and efficiently.
API Development:
API development is the process of designing, creating and developing application programming interfaces (APIs) for various software applications. APIs are used by software and hardware systems to communicate with each other. In recent years, there has been a tremendous increase in the number of API-based services on the internet as well as mobile applications that have transformed conventional smartphone usage.
Manufacturing:
Manufacturing is the process of converting raw materials into a finished product. In contract development and manufacturing organizations (CDMOs), manufacturers are engaged in producing clinical trial materials such as containers, tubes, bags, and vials. The work is divided among numerous companies that bid for the project. Manufacturing services are provided by pharmaceutical firms as well as contract research organizations (CROs).
Application Insights:
The pharmaceutical company segment dominated the global bio contract development and manufacturing organizations (CDMO) market in 2017. This is attributed to factors such as presence of a large number of biopharmaceutical companies, which are engaged in the research and development activities for developing new drugs. These companies are also involved in the production and commercialization of medicines.
Moreover, there has been an increase in R&D investments by these companies for discovering novel molecules that can be used to treat various diseases. For instance, Pfizer Inc., one of America's largest pharmaceutical companies has invested around USD 1 billion annually on discovery research till 2020. Such initiatives by these players have led to an increased demand for bio-contracted products from contract manufacturers over recent years.
The generic company segment is expected to grow at a significant rate over the forecast period owing to increasing FDA approvals coupled with rising awareness about biosimilars among healthcare professionals.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biopharmaceutical manufacturing organizations and CDMOs has fueled growth in this region. In addition, the high cost of development and approval processes is also driving companies to outsource these processes to countries with low labor costs thus increasing opportunities for bio contract development & manufacturing organizations (CDMOs).
Asia Pacific is expected to grow at a lucrative rate over the forecast period owing to factors such as growing economy, improving healthcare infrastructure, rising awareness about new treatment options among patients coupled with an increase in demand for generic drugs leading towards lower prices. These aforementioned factors are expected drive regional growth over the forecast period.
Growth Factors:
- Increasing demand for biologics from the pharmaceutical and biotechnology industries
- Growing number of biosimilars in development and commercialization
- Rising incidence of chronic diseases that require treatment with biologics
- Proliferation of contract research organizations (CROs) that offer bio CDMO services
- Expansion of the global biosimilars market
Scope Of The Report
Report Attributes
Report Details
Report Title
Bio Contract Development and Manufacturing Organizations (CDMOs) Market Research Report
By Type
API Development, Manufacturing, Drug Delivery, Bio Contract Development and Manufacturing Organizations (CDMOs
By Application
Pharmaceutical Company, Biotechnology Company, Generic Company
By Companies
Lonza, Boehringer ?Ingelheim, Celltrion, Fujifilm, Selexis, Ology Bio, Ardena, Catalent, AGC, Amgen, Bio Contract Development and Manufacturing Organizations (CDMOs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
246
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Bio Contract Development and Manufacturing Organizations (CDMOs) Market Report Segments:
The global Bio Contract Development and Manufacturing Organizations (CDMOs) market is segmented on the basis of:
Types
API Development, Manufacturing, Drug Delivery, Bio Contract Development and Manufacturing Organizations (CDMOs
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pharmaceutical Company, Biotechnology Company, Generic Company
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lonza
- Boehringer ?Ingelheim
- Celltrion
- Fujifilm
- Selexis
- Ology Bio
- Ardena
- Catalent
- AGC
- Amgen
- Bio Contract Development and Manufacturing Organizations (CDMOs
 Market Overview.svg)
Highlights of The Bio Contract Development and Manufacturing Organizations (CDMOs) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- API Development
- Manufacturing
- Drug Delivery
- Bio Contract Development and Manufacturing Organizations (CDMOs
- By Application:
- Pharmaceutical Company
- Biotechnology Company
- Generic Company
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bio Contract Development and Manufacturing Organizations (CDMOs) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bio Contract Development and Manufacturing Organizations (CDMOs) are organizations that help companies develop, manufacture, and commercialize products using biotechnology. CDMOs can provide a variety of services including product development, manufacturing, marketing, and distribution.
Some of the key players operating in the bio contract development and manufacturing organizations (cdmos) market are Lonza, Boehringer ?Ingelheim, Celltrion, Fujifilm, Selexis, Ology Bio, Ardena, Catalent, AGC, Amgen, Bio Contract Development and Manufacturing Organizations (CDMOs.
The bio contract development and manufacturing organizations (cdmos) market is expected to register a CAGR of 9.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Bio Contract Development and Manufacturing Organizations (CDMOs) Market - Supply Chain
4.5. Global Bio Contract Development and Manufacturing Organizations (CDMOs) Market Forecast
4.5.1. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Absolute $ Opportunity
5. Global Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Type
5.3.1. API Development
5.3.2. Manufacturing
5.3.3. Drug Delivery
5.3.4. Bio Contract Development and Manufacturing Organizations (CDMOs
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Application
6.3.1. Pharmaceutical Company
6.3.2. Biotechnology Company
6.3.3. Generic Company
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Bio Contract Development and Manufacturing Organizations (CDMOs) Demand Share Forecast, 2019-2026
9. North America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Application
9.4.1. Pharmaceutical Company
9.4.2. Biotechnology Company
9.4.3. Generic Company
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Type
9.7.1. API Development
9.7.2. Manufacturing
9.7.3. Drug Delivery
9.7.4. Bio Contract Development and Manufacturing Organizations (CDMOs
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Bio Contract Development and Manufacturing Organizations (CDMOs) Demand Share Forecast, 2019-2026
10. Latin America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Application
10.4.1. Pharmaceutical Company
10.4.2. Biotechnology Company
10.4.3. Generic Company
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Type
10.7.1. API Development
10.7.2. Manufacturing
10.7.3. Drug Delivery
10.7.4. Bio Contract Development and Manufacturing Organizations (CDMOs
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Bio Contract Development and Manufacturing Organizations (CDMOs) Demand Share Forecast, 2019-2026
11. Europe Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Application
11.4.1. Pharmaceutical Company
11.4.2. Biotechnology Company
11.4.3. Generic Company
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Type
11.7.1. API Development
11.7.2. Manufacturing
11.7.3. Drug Delivery
11.7.4. Bio Contract Development and Manufacturing Organizations (CDMOs
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Bio Contract Development and Manufacturing Organizations (CDMOs) Demand Share, 2019-2026
12. Asia Pacific Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Application
12.4.1. Pharmaceutical Company
12.4.2. Biotechnology Company
12.4.3. Generic Company
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Type
12.7.1. API Development
12.7.2. Manufacturing
12.7.3. Drug Delivery
12.7.4. Bio Contract Development and Manufacturing Organizations (CDMOs
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Bio Contract Development and Manufacturing Organizations (CDMOs) Demand Share, 2019-2026
13. Middle East & Africa Bio Contract Development and Manufacturing Organizations (CDMOs) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Application
13.4.1. Pharmaceutical Company
13.4.2. Biotechnology Company
13.4.3. Generic Company
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Bio Contract Development and Manufacturing Organizations (CDMOs) Market Size and Volume Forecast by Type
13.7.1. API Development
13.7.2. Manufacturing
13.7.3. Drug Delivery
13.7.4. Bio Contract Development and Manufacturing Organizations (CDMOs
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Bio Contract Development and Manufacturing Organizations (CDMOs) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Bio Contract Development and Manufacturing Organizations (CDMOs) Market: Market Share Analysis
14.2. Bio Contract Development and Manufacturing Organizations (CDMOs) Distributors and Customers
14.3. Bio Contract Development and Manufacturing Organizations (CDMOs) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Lonza
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Boehringer ?Ingelheim
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celltrion
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Fujifilm
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Selexis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Ology Bio
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Ardena
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Catalent
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. AGC
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Amgen
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bio Contract Development and Manufacturing Organizations (CDMOs
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1.&n
